Dr. Jay Reddy, MD, PHD
Claim this profileM D Anderson Cancer Center
Studies Squamous Cell Carcinoma
Studies Skin Cancer
2 reported clinical trials
6 drugs studied
Area of expertise
1Squamous Cell Carcinoma
p16 negative
PD-1 positive
PD-L1 positive
2Skin Cancer
p16 negative
PD-1 positive
PD-L1 positive
Affiliated Hospitals
Clinical Trials Jay Reddy, MD, PHD is currently running
Stereotactic Body Radiation Therapy
for Head and Neck Cancer
To learn if it is effective to use advanced radiation treatment techniques (stereotactic radiation or "SBRT") to safely deliver a strong dose of radiation to your tumor in a shorter period of time than would typically be feasible with traditional methods.
Recruiting1 award Phase 2
NBTXR3 + Radiation + Pembrolizumab
for Head and Neck Cancer
This phase II trial investigates the effect of NBTXR3, radiation therapy, and pembrolizumab in treating patients with head and neck squamous cancer that has come back (recurrent) or has spread to other places in the body (metastatic). NBTXR3 may cause cell destruction when activated by radiation. Radiation therapy, such as stereotactic body radiation therapy, uses special equipment to position a patient and deliver radiation to tumors with high precision. This method may kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. And hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving NBTXR3, radiation therapy, and pembrolizumab may kill more tumor cells.
Recruiting2 awards Phase 233 criteria
More about Jay Reddy, MD, PHD
Clinical Trial Related1 year of experience running clinical trials · Led 2 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Jay Reddy, MD, PHD has experience with
- Hypofractionated Radiation Therapy
- NBTXR3
- Pembrolizumab
- Stereotactic Body Radiation Therapy
- Stereotactic Body Radiotherapy
- Traditional Palliation
Breakdown of trials Jay Reddy, MD, PHD has run
Squamous Cell Carcinoma
Skin Cancer
Head and Neck Squamous Cell Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Jay Reddy, MD, PHD specialize in?
Jay Reddy, MD, PHD focuses on Squamous Cell Carcinoma and Skin Cancer. In particular, much of their work with Squamous Cell Carcinoma has involved p16 negative patients, or patients who are PD-1 positive.
Is Jay Reddy, MD, PHD currently recruiting for clinical trials?
Yes, Jay Reddy, MD, PHD is currently recruiting for 2 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Jay Reddy, MD, PHD has studied deeply?
Yes, Jay Reddy, MD, PHD has studied treatments such as Hypofractionated Radiation Therapy, NBTXR3, Pembrolizumab.
What is the best way to schedule an appointment with Jay Reddy, MD, PHD?
Apply for one of the trials that Jay Reddy, MD, PHD is conducting.
What is the office address of Jay Reddy, MD, PHD?
The office of Jay Reddy, MD, PHD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.